Research dossier / Melanocortin tripeptide
KPV peptide is the anti-inflammatory C-terminal tripeptide of alpha-MSH — here is what the research actually establishes.
A sober, cited reading of three amino acids: how lysine-proline-valine suppresses inflammation, why the gut takes it up through a dedicated transporter, and exactly where compounded access stands.
The short version
KPV peptide is a tiny molecule — just three amino acids, lysine, proline, and valine — clipped from the tail end of a natural hormone called alpha-MSH (alpha-melanocyte-stimulating hormone, a signaling molecule the body uses to calm inflammation and tint skin). KPV keeps the hormone's calming, anti-inflammatory side but drops its skin-coloring side. In lab dishes and in mice it quiets the cell machinery that drives inflammation, and the gut pulls it in through a dedicated doorway. Every finding here comes from animal or cell studies — there are no human trials yet, and KPV is sold for laboratory research only.
KPV: the C-terminal tripeptide of alpha-MSH
KPV is the C-terminal tripeptide of alpha-MSH — residues 11 through 13 of the parent hormone [1]. In the research literature this fragment is studied as a standalone anti-inflammatory agent that retains the parent hormone's calming activity while lacking its pigmentary (skin-darkening) action [4]. That separation is the defining feature of KPV across three decades of work: a melanocortin-derived molecule that dampens inflammation without the melanogenic effect of full alpha-MSH [4].
The reproducible result is anti-inflammatory signaling. In human intestinal epithelial cells (the lining cells of the gut) and immune cells, nanomolar KPV — concentrations as low as 10 nM — reduced activation of NF-kB (nuclear factor kappa B, a master switch that turns on pro-inflammatory genes) and MAP-kinase (MAPK, a relay enzyme for inflammatory signals), and cut secretion of pro-inflammatory cytokines [1]. The effect appears to be largely independent of the classical melanocortin receptors: KPV's anti-inflammatory action was retained in MC1R-deficient mice (animals lacking the melanocortin-1 receptor), pointing to a receptor-independent mechanism [2].
What the KPV peptide literature has demonstrated
The largest body of KPV research is in the gut. Oral KPV reduced the severity of chemically induced colitis in two standard mouse models — DSS-induced and TNBS-induced colitis [1]. Treated animals recovered earlier, regained body weight more strongly, and showed less colonic inflammatory infiltrate and lower myeloperoxidase activity (a neutrophil enzyme used as a tissue marker of inflammation) [2]. A key mechanistic detail explains why the gut is so central: KPV is carried directly into intestinal lining cells by PepT1 (SLC15A1), a di/tripeptide transporter that pulls small peptides into the cells lining the gut and is upregulated in inflamed intestinal tissue [1].
The effect is not limited to the intestine. Topical KPV accelerated corneal wound healing in rabbits: by 60 hours, 8 of 8 corneas treated with KPV were completely re-epithelialized versus none of the placebo-treated corneas [6]. A comprehensive review situates KPV within a peptide family with protective effects across fever, dermatitis, vasculitis, ocular, gastrointestinal, and organ-injury models [4]. You can read the full record on the KPV colitis research page and trace each claim to its study in the KPV references.
Identity: Lysine-Proline-Valine in one paragraph
Lysine-Proline-Valine is the full chemical name of KPV — a linear tripeptide written H-Lys-Pro-Val-OH, molecular formula C16H30N4O4, molecular weight 342.44 Da, CAS 67727-97-3 [4]. It corresponds to the C-terminal three residues (11-13) of alpha-MSH and is not an independently circulating hormone in its own right [4]. Because it is small and unprotected, free KPV is expected to be degraded quickly by peptidases, which is why so much recent work wraps it in carriers — a problem the dedicated KPV oral bioavailability page covers through PepT1-targeted delivery. KPV is not an approved drug; the KPV legal status page reads the regulatory record straight from FDA's own pages.
How to read this site
This is an editorial research digest, organized the way a regulatory analyst would organize it: what the cited literature genuinely establishes, what remains preclinical, and where the access question stands. The KPV colitis research page covers mechanism and the strongest studies. The PepT1-targeted delivery page covers the delivery problem and gut uptake. The KPV dosage in research page describes the doses used in animal and cell studies, never a human regimen. The FDA 503A compounding access page reads FDA's position. And the KPV frequently asked questions page answers the questions readers actually ask, each cited where it makes a quantitative claim.